Stage IV lung squamous cell cancer complicated by adrenal insufficiency during immunotherapy

Patient Info: Anonymized, male, 50s | Stage IV

Mediastinal and hilar lymph nodes improved on treatment. Immunotherapy remained paused because of adrenal insufficiency, and updated follow-up found no recurrence or additional metastasis.

PubMed CentralRead more →

Stage IV lung squamous cell cancer with bone metastasis and immunotherapy-related adrenal insufficiency

Patient Info: Anonymized, male, 70+ | Stage IV

Metastatic Site: rib/bone

After earlier progression with rib/bone destruction, the latest chest CT showed lung lesions similar to prior imaging. Tislelizumab remained paused because of adrenal insufficiency.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Lenny's Survivor Story

Patient Info: Lenny, Male, 50s | Stage IV

Biomarkers: PD-L1 expression positive

Metastatic Site: right femur; brain/cerebellum

As of July 2024, Lenny described himself as NED/no evidence of disease after surgery, CyberKnife radiation, chemotherapy, and Keytruda-based immunotherapy.

The Patient StoryRead more →

RET-rearranged metastatic lung cancer responding to selpercatinib after pralsetinib

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: KIF5B-RET fusion; PD-L1 negative

Metastatic Site: brain

More than 5 years after her 2018 diagnosis, selpercatinib was ongoing after 8 months with continued brain response and stable lung disease.

PubMed CentralRead more →

Five-year survival with extensive-stage small cell lung cancer on atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: bilateral lungs, cervical lymph nodes

Five years after diagnosis with extensive-stage small cell lung cancer, he was alive and well on maintenance atezolizumab with no further documented progression after the 2020–2021 rechallenge, reaching 60 months overall survival and about 44 months progression-free survival.

PubMed CentralRead more →

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed CentralRead more →

Small cell lung cancer discovered after recurrent pneumothorax

Patient Info: Anonymized, male, 60s

Follow-up chest CT showed only postsurgical changes with no evidence of tumor, and he was doing well under oncology follow-up.

PubMed CentralRead more →

Treatment-related lung injury during therapy for Stage IV squamous lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

A 63-year-old man with Stage IV squamous lung cancer developed interstitial lung disease soon after starting chemotherapy and immunotherapy, with respiratory findings improving after steroid treatment.

PubMed CentralRead more →

Radiation pneumonitis during chemoradiotherapy for Stage III squamous lung cancer

Patient Info: Anonymized, Male, 70+ | Stage III

An 88-year-old man with Stage III squamous lung cancer developed radiation pneumonitis during chemoradiotherapy, with symptoms and imaging improving after steroid treatment.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma in Li-Fraumeni syndrome: relapse-free after lobectomy and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Lung tumor had EGFR exon 19 deletion. Germline TP53 variant was consistent with Li-Fraumeni syndrome; prior breast cancers were HER2 positive.

As of July 2024, she was free of relapse 2 years after left inferior lobectomy and pemetrexed/cisplatin for EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed CentralRead more →

Stage IV pulmonary mucoepidermoid carcinoma with an ALK fusion responding to targeted therapy

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EML4-ALK fusion; PD-L1 <1%

Metastatic Site: liver

By December 2023, oral ALK-targeted therapy was ongoing with a partial response, improved symptoms, weight gain, and marked shrinkage of lung and metastatic disease.

PubMed CentralRead more →

Stage IVA lung adenocarcinoma with solitary brain metastasis: pCR after brain surgery, chemoradiation, immunotherapy, and lobectomy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 75%; negative for driver gene mutations and translocations

Metastatic Site: brain

As of May 2024, he had no recurrence after brain metastasis resection and radiation, carboplatin/pemetrexed/atezolizumab, robot-assisted right upper lobectomy with pathologic complete response, and 13 cycles of maintenance atezolizumab.

PubMed CentralRead more →

Stage 4 lung adenocarcinoma: complete response on immunotherapy combination

Patient Info: Anonymized, Male | Stage IV

Biomarkers: No targetable mutation found. Tissue showed TP53/ARID1A; liquid biopsy added KEAP1, and SMARCA4. PD-L1 not evaluable.

Metastatic Site: bilateral lung nodules, left adrenal gland

As of May 2024, metastatic lung adenocarcinoma had a complete radiologic response lasting more than 14 months on pembrolizumab maintenance, and a new PET-avid lung nodule was benign inflammation rather than cancer.

PubMed CentralRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Survivor Story

Patient Info: Daniel West, Male | Stage II

Biomarkers: EGFR alteration

At the latest report, Daniel had no evidence of active cancer; small lung nodules were being monitored without progression while he continued osimertinib.

Small cell lung cancer with SIADH that progressed after an initial response to treatment

Patient Info: Anonymized, female, 60s | Stage IV

Metastatic Site: liver

The cancer progressed with disseminated liver metastases, and she died from liver failure in February 2021.

PubMed CentralRead more →

Stage 4 lung cancer stable on durvalumab immunotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Metastatic Site: brain, pancreas, liver

Stage IV small cell lung cancer remained stable after durvalumab, platinum chemotherapy, radiation, and 1 year of durvalumab monotherapy; severe right sternoclavicular joint arthritis resolved after infliximab, and immunotherapy was suspended for 1 year.

PubMed CentralRead more →

Stage IV small cell lung cancer with metastases involving bone and both eye muscles

Patient Info: Anonymized, male, 40s | Stage IV

Metastatic Site: bone; bilateral extraocular muscles (orbits)

He died 5 months after presenting with bilateral orbital involvement while receiving palliative treatment for Stage IV small cell lung cancer.

PubMed CentralRead more →

Stage III small cell lung cancer complicated by a tracheomediastinal fistula during chemoradiation

Patient Info: Anonymized, male, 70+ | Stage III

Four months after treatment began, there was no evident cancer recurrence, although the persistent fistula remained under consideration for repair.

PubMed CentralRead more →

Eye complication (corneal irritation) as a rare side effect of nivolumab immunotherapy

Patient Info: Anonymized, Female

One year after nivolumab was stopped, there was no progression of the lung cancer or secondary lesions, and she remained under surveillance.

PubMed CentralRead more →

Stage II Lung Cancer: Ed's Survivor Story

Patient Info: Ed Ackerman, Male, 60s | Stage II

Follow-up tests and scans showed Ed was cancer-free after lung resection and 4 rounds of chemotherapy for Stage IIA lung cancer.

Cleveland ClinicRead more →

Stage IV lung adenocarcinoma complicated by visceral leishmaniasis during chemotherapy

Patient Info: Anonymized, male, 50s | Stage IV

Biomarkers: EGFR wild-type; ALK negative; ROS negative; PD-L1 negative

Imaging showed progression while maintenance pemetrexed was temporarily interrupted; pemetrexed was then restarted during treatment for visceral leishmaniasis.

PubMed CentralRead more →

ALK-positive lung adenocarcinoma complicated by crizotinib-associated kidney and liver cysts

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ALK fusion

Metastatic Site: bone

After switching from crizotinib to alectinib, the lung cancer and hilar lymph nodes remained stable at the latest follow-up described.

PubMed CentralRead more →

Stage III squamous lung cancer complicated by a fatal postoperative bronchopleural fistula

Patient Info: Anonymized, male, 40s | Stage III

He developed a postoperative bronchopleural fistula with pulmonary infection and worsening respiratory failure, and died on December 2, 2020.

PubMed CentralRead more →